BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today ...
NEWTON, Mass., November 13, 2025--(BUSINESS WIRE)--Inflammasome Therapeutics (https://www.inflam.com), a clinical-stage biotech company developing a new class of drugs, Kamuvudines, for ophthalmic and ...
Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
Inflammasome Therapeutics (https://www.inflam.com), a clinical-stage biotech company developing a new class of drugs, Kamuvudines, for ophthalmic and neurological conditions, announced the company has ...
BOSTON, Nov. 25, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its Phase 2 clinical trial evaluating intranasal ...
Investigational products showing positive results in the Healey ALS MyMatch program may advance to the HEALEY ALS Platform Trial or proceed directly to standalone Phase 3 trials. ALS is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results